Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...
Pharmaceutical Technology on MSN
Corcept’s first-in-class ovarian cancer drug gains FDA approval
The drug can now be prescribed alongside nab-paclitaxel for patients with ovarian cancer who have relapsed between one and ...
Almost four months ahead of schedule, Corcept Therapeutics' selective glucocorticoid receptor antagonist (SGRA) relacorilant ...
A new study headed by teams at the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), and Open Targets has indicated how mutations that cause cancer drug resistance fall ...
Scientists have uncovered a hidden reason why cancer treatments don’t work equally well for everyone. Certain drugs can ...
China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. Wednesday, Chinese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results